DE69924488D1 - Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms - Google Patents

Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms

Info

Publication number
DE69924488D1
DE69924488D1 DE69924488T DE69924488T DE69924488D1 DE 69924488 D1 DE69924488 D1 DE 69924488D1 DE 69924488 T DE69924488 T DE 69924488T DE 69924488 T DE69924488 T DE 69924488T DE 69924488 D1 DE69924488 D1 DE 69924488D1
Authority
DE
Germany
Prior art keywords
reizdary
norcisapride
syndrome
treatment
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69924488T
Other languages
English (en)
Other versions
DE69924488T2 (de
Inventor
D Rubin
J Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of DE69924488D1 publication Critical patent/DE69924488D1/de
Application granted granted Critical
Publication of DE69924488T2 publication Critical patent/DE69924488T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69924488T 1998-06-15 1999-06-10 Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms Expired - Fee Related DE69924488T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8922598P 1998-06-15 1998-06-15
US89225P 1998-06-15
US12223699P 1999-03-01 1999-03-01
US122236P 1999-03-01
PCT/US1999/013100 WO1999065490A2 (en) 1998-06-15 1999-06-10 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders

Publications (2)

Publication Number Publication Date
DE69924488D1 true DE69924488D1 (de) 2005-05-04
DE69924488T2 DE69924488T2 (de) 2005-09-08

Family

ID=26780367

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924488T Expired - Fee Related DE69924488T2 (de) 1998-06-15 1999-06-10 Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms

Country Status (24)

Country Link
US (2) US6559165B1 (de)
EP (1) EP1087765B1 (de)
JP (1) JP2003522103A (de)
KR (3) KR20060020739A (de)
CN (1) CN1312716A (de)
AR (1) AR020327A1 (de)
AT (1) ATE291916T1 (de)
AU (1) AU764474B2 (de)
BG (1) BG105097A (de)
BR (1) BR9911302A (de)
CA (1) CA2334369A1 (de)
CZ (1) CZ20004736A3 (de)
DE (1) DE69924488T2 (de)
ES (1) ES2237117T3 (de)
HK (1) HK1040059A1 (de)
HU (1) HUP0102026A3 (de)
IL (1) IL140117A0 (de)
IS (1) IS5755A (de)
NO (1) NO20006358L (de)
NZ (3) NZ535055A (de)
PL (1) PL345325A1 (de)
SK (1) SK19062000A3 (de)
TR (6) TR200003707T2 (de)
WO (1) WO1999065490A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US8287554B2 (en) 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
US5116407A (en) 1988-10-13 1992-05-26 Courtaulds Coatings Limited Antifouling coatings
JPH02188523A (ja) 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2126354C (en) * 1991-12-21 2006-07-11 Gareth John Sanger Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH08502031A (ja) 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
WO1994001112A1 (en) 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
CA2166730A1 (en) 1993-07-06 1995-01-19 Robert T. Sims H2 antagonist-gastrointestinal motility agent combinations
US5407953A (en) 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
US5502067A (en) 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
HUP0003078A3 (en) * 1997-07-11 2002-02-28 Janssen Pharmaceutica Nv (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
DE69924375T2 (de) 1998-06-15 2005-08-11 Sepracor Inc. Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms

Also Published As

Publication number Publication date
TR200103757T2 (tr) 2002-06-21
ATE291916T1 (de) 2005-04-15
TR200003707T2 (tr) 2001-06-21
AU764474B2 (en) 2003-08-21
AR020327A1 (es) 2002-05-08
US7064138B2 (en) 2006-06-20
JP2003522103A (ja) 2003-07-22
NO20006358D0 (no) 2000-12-13
BG105097A (en) 2002-02-28
SK19062000A3 (sk) 2001-07-10
TR200103760T2 (tr) 2002-06-21
BR9911302A (pt) 2001-03-13
CN1312716A (zh) 2001-09-12
TR200103758T2 (tr) 2002-06-21
CA2334369A1 (en) 1999-12-23
NZ526108A (en) 2004-10-29
NO20006358L (no) 2001-02-13
TR200103762T2 (tr) 2002-05-21
IS5755A (is) 2000-12-08
NZ508825A (en) 2003-09-26
HUP0102026A3 (en) 2002-12-28
EP1087765A2 (de) 2001-04-04
HUP0102026A2 (hu) 2001-11-28
PL345325A1 (en) 2001-12-17
EP1087765B1 (de) 2005-03-30
AU4678499A (en) 2000-01-05
KR20060067985A (ko) 2006-06-20
CZ20004736A3 (cs) 2001-09-12
KR20060020739A (ko) 2006-03-06
KR20010052740A (ko) 2001-06-25
WO1999065490A2 (en) 1999-12-23
NZ535055A (en) 2006-04-28
DE69924488T2 (de) 2005-09-08
US6559165B1 (en) 2003-05-06
IL140117A0 (en) 2002-02-10
WO1999065490A3 (en) 2000-04-13
US20030158229A1 (en) 2003-08-21
HK1040059A1 (zh) 2002-05-24
TR200103759T2 (tr) 2002-06-21
ES2237117T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69722635D1 (de) Behandlung von materialien zur verbesserung der behandlung von viskoelastische flüssigkeiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE60037213D1 (de) Verwendung von Reinigungsgas
DE69817446D1 (de) Behandlung von diabetes
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
ATE253383T1 (de) Behandlung von in der luft enthaltenen mikroorganismen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69924488D1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE69132782D1 (de) Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee